Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Boryung DTaP-IPV is a combination vaccine developed by Boryung Biopharma for the active immunization of infants and children against diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis (polio). The vaccine is a biological product containing diphtheria toxoid, tetanus toxoid, acellular pertussis antigens derived from *Bordetella pertussis*, and inactivated poliovirus. It functions by inducing protective antibody-mediated immunity against the four target pathogens. Administered via intramuscular injection, it is typically used in a primary vaccination series at 2, 4, and 6 months of age, followed by a booster dose between 4 and 6 years of age. The product is available in a prefilled syringe formulation and is an integral part of the National Immunization Program in South Korea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Boryung DTaP-IPV.